Keywords: USA, FDA, Boehringer Ingelheim, Pradaxa, Bleeding risks
FDA reviews Pradaxa bleeding risk
Article | 08 December 2011
Post-marketing reports of serious bleeding events in patients taking Pradaxa (dabigatran etexilate mesylate), a blood thinner from independent German drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
